fluoxetine has been researched along with Autism in 41 studies
Fluoxetine: The first highly specific serotonin uptake inhibitor. It is used as an antidepressant and often has a more acceptable side-effects profile than traditional antidepressants.
fluoxetine : A racemate comprising equimolar amounts of (R)- and (S)-fluoxetine. A selective serotonin reuptake inhibitor (SSRI), it is used (generally as the hydrochloride salt) for the treatment of depression (and the depressive phase of bipolar disorder), bullimia nervosa, and obsessive-compulsive disorder.
N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine : An aromatic ether consisting of 4-trifluoromethylphenol in which the hydrogen of the phenolic hydroxy group is replaced by a 3-(methylamino)-1-phenylpropyl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "A positive effect of fluoxetine has been shown in some children with autism." | 9.15 | Effects of fluoxetine treatment on striatal dopamine transporter binding and cerebrospinal fluid insulin-like growth factor-1 in children with autism. ( Kokki, H; Kuikka, J; Makkonen, I; Riikonen, R; Turpeinen, U, 2011) |
| "Retrospective chart reviews of seven adolescent and young adults with autistic disorder treated with fluoxetine alone or in combination with other medications were performed." | 9.08 | Fluoxetine in treatment of adolescent patients with autism: a longitudinal open trial. ( Fatemi, SH; Khan, L; Realmuto, GM; Thuras, P, 1998) |
| "Thirty-seven children, aged between 2 and 7 years, with idiopathic autism underwent an open-label trial of fluoxetine treatment." | 7.70 | Effects of fluoxetine treatment in young children with idiopathic autism. ( DeLong, GR; McSwain Kamran, M; Teague, LA, 1998) |
| "An open trial of pharmacological treatment with fluoxetine, ranging from 20 mg every other day to 80 mg per day, led to a significant improvement in Clinical Global Impressions ratings of Clinical Severity in 15 of 23 subjects with autistic disorder and 10 of 16 subjects with mental retardation." | 7.68 | Fluoxetine treatment of children and adults with autistic disorder and mental retardation. ( Cook, EH; Jaselskis, C; Leventhal, BL; Rowlett, R, 1992) |
| "Fluoxetine is a selective serotonin reuptake inhibitor (SSRI) that reduces obsessive-compulsive symptoms." | 6.94 | The SOFIA Study: Negative Multi-center Study of Low Dose Fluoxetine on Repetitive Behaviors in Children and Adolescents with Autistic Disorder. ( Arnold, LE; Attalla, A; Bregman, JD; Cartwright, C; Childress, A; Chugani, H; Frazier, J; Ginsberg, L; Handen, BL; Hendren, R; Herscu, P; King, B; Kolevzon, A; Melmed, R; Minshew, N; Mintz, M; Murphy, T; Owley, T; Sikich, L; Snape, MF, 2020) |
| "Fluoxetine therefore has inverse effects on mPFC activation in ASD and ADHD during reversal learning, suggesting dissociated underlying serotonin abnormalities." | 6.80 | Inverse Effect of Fluoxetine on Medial Prefrontal Cortex Activation During Reward Reversal in ADHD and Autism. ( Barrett, N; Brammer, M; Chantiluke, K; Giampietro, V; Murphy, DG; Rubia, K; Simmons, A, 2015) |
| "A positive effect of fluoxetine has been shown in some children with autism." | 5.15 | Effects of fluoxetine treatment on striatal dopamine transporter binding and cerebrospinal fluid insulin-like growth factor-1 in children with autism. ( Kokki, H; Kuikka, J; Makkonen, I; Riikonen, R; Turpeinen, U, 2011) |
| "The regional metabolic effects of fluoxetine were examined in patients with autism spectrum disorders." | 5.09 | Effect of fluoxetine on regional cerebral metabolism in autistic spectrum disorders: a pilot study. ( Bienstock, C; Buchsbaum, BR; Buchsbaum, MS; Cartwright, C; Haznedar, MM; Hollander, E; Mosovich, S; Robins, D; Solimando, A; Spiegel-Cohen, J; Tang, C; Wei, TC, 2001) |
| "Retrospective chart reviews of seven adolescent and young adults with autistic disorder treated with fluoxetine alone or in combination with other medications were performed." | 5.08 | Fluoxetine in treatment of adolescent patients with autism: a longitudinal open trial. ( Fatemi, SH; Khan, L; Realmuto, GM; Thuras, P, 1998) |
| " Search terms included autism, autistic disorder, citalopram, fluoxetine, fluvoxamine, paroxetine, selective serotonin-reuptake inhibitors, and sertraline." | 4.82 | Treating functional impairment of autism with selective serotonin-reuptake inhibitors. ( Eichner, SF; Jones, JR; Moore, ML, 2004) |
| "We isolated deep layer prefrontal circuits in brain slices then used single-photon GCaMP imaging to record activity from many (50 to 100) neurons simultaneously to study patterns of spontaneous activity generated by these circuits under normal conditions and in two etiologically distinct models of autism: mice exposed to valproic acid in utero and Fmr1 knockout mice." | 3.83 | Putative Microcircuit-Level Substrates for Attention Are Disrupted in Mouse Models of Autism. ( Horn, ME; Luongo, FJ; Sohal, VS, 2016) |
| " We differentiated and treated human SK-N-SH neuroblastoma cells with a mixture (fluoxetine, carbamazepine and venlafaxine) and valproate (used as a positive control to induce autism-associated profiles), followed by transcriptome analysis with RNA-Seq approach." | 3.83 | Psychoactive pharmaceuticals at environmental concentrations induce in vitro gene expression associated with neurological disorders. ( Kaushik, G; Thomas, MA; Xia, Y; Yang, L, 2016) |
| "One hundred and twenty-nine children, 2 to 8 years old, with idiopathic autistic spectrum disorder diagnosed by standard instruments (Childhood Austim Ratings Scale and Autism Diagnostic Observation Schedule) were treated with fluoxetine (0." | 3.71 | Fluoxetine response in children with autistic spectrum disorders: correlation with familial major affective disorder and intellectual achievement. ( Burch, S; DeLong, GR; Ritch, CR, 2002) |
| "Twenty-one pediatric subjects with diagnoses of autistic disorder or other pervasive developmental disorders, 6-15 years old and stabilized with a consistent dose of fluvoxamine or fluoxetine, were recruited for the study; 16 successfully completed the imaging protocol." | 3.71 | Fluorine magnetic resonance spectroscopy measurement of brain fluvoxamine and fluoxetine in pediatric patients treated for pervasive developmental disorders. ( Cowan, C; Dager, SR; Dawson, G; Strauss, WL; Unis, AS, 2002) |
| "Thirty-seven children, aged between 2 and 7 years, with idiopathic autism underwent an open-label trial of fluoxetine treatment." | 3.70 | Effects of fluoxetine treatment in young children with idiopathic autism. ( DeLong, GR; McSwain Kamran, M; Teague, LA, 1998) |
| "An open trial of pharmacological treatment with fluoxetine, ranging from 20 mg every other day to 80 mg per day, led to a significant improvement in Clinical Global Impressions ratings of Clinical Severity in 15 of 23 subjects with autistic disorder and 10 of 16 subjects with mental retardation." | 3.68 | Fluoxetine treatment of children and adults with autistic disorder and mental retardation. ( Cook, EH; Jaselskis, C; Leventhal, BL; Rowlett, R, 1992) |
| "Depressive illness in a patient with Down's syndrome and autism responded to fluoxetine." | 3.68 | Depression in autistic disorder. ( Ghaziuddin, M; Tsai, L, 1991) |
| "Fluoxetine is a selective serotonin reuptake inhibitor (SSRI) that reduces obsessive-compulsive symptoms." | 2.94 | The SOFIA Study: Negative Multi-center Study of Low Dose Fluoxetine on Repetitive Behaviors in Children and Adolescents with Autistic Disorder. ( Arnold, LE; Attalla, A; Bregman, JD; Cartwright, C; Childress, A; Chugani, H; Frazier, J; Ginsberg, L; Handen, BL; Hendren, R; Herscu, P; King, B; Kolevzon, A; Melmed, R; Minshew, N; Mintz, M; Murphy, T; Owley, T; Sikich, L; Snape, MF, 2020) |
| "Fluoxetine therefore has inverse effects on mPFC activation in ASD and ADHD during reversal learning, suggesting dissociated underlying serotonin abnormalities." | 2.80 | Inverse Effect of Fluoxetine on Medial Prefrontal Cortex Activation During Reward Reversal in ADHD and Autism. ( Barrett, N; Brammer, M; Chantiluke, K; Giampietro, V; Murphy, DG; Rubia, K; Simmons, A, 2015) |
| "improves the core features of autism (social interaction, communication and behavioural problems);2." | 2.49 | Selective serotonin reuptake inhibitors (SSRIs) for autism spectrum disorders (ASD). ( Brignell, A; Hazell, P; Randall, M; Silove, N; Williams, K, 2013) |
| "improves the core features of autism (social interaction, communication and behavioural problems); 2." | 2.46 | Selective serotonin reuptake inhibitors (SSRIs) for autism spectrum disorders (ASD). ( Hazell, P; Silove, N; Wheeler, DM; Williams, K, 2010) |
| "A majority of cases of idiopathic autism in children likely result from unknown environmental triggers in genetically susceptible individuals." | 1.46 | Dysregulation of autism-associated synaptic proteins by psychoactive pharmaceuticals at environmental concentrations. ( Kaushik, G; Pfau, JC; Thomas, MA; Xia, Y, 2017) |
| "Idiopathic autism, caused by genetic susceptibility interacting with unknown environmental triggers, has increased dramatically in the past 25 years." | 1.38 | Psychoactive pharmaceuticals induce fish gene expression profiles associated with human idiopathic autism. ( Klaper, RD; Thomas, MA, 2012) |
| "We report 2 patients with autism and mental retardation who developed catatonic symptoms at the onset of puberty." | 1.36 | Onset of catatonia at puberty: electroconvulsive therapy response in two autistic adolescents. ( Barbosa, V; Ghaziuddin, M; Ghaziuddin, N; Gih, D; Maixner, DF, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 17 (41.46) | 18.2507 |
| 2000's | 7 (17.07) | 29.6817 |
| 2010's | 13 (31.71) | 24.3611 |
| 2020's | 4 (9.76) | 2.80 |
| Authors | Studies |
|---|---|
| Gioia, R | 1 |
| Seri, T | 1 |
| Diamanti, T | 1 |
| Fimmanò, S | 1 |
| Vitale, M | 1 |
| Ahlenius, H | 1 |
| Kokaia, Z | 1 |
| Tirone, F | 1 |
| Micheli, L | 1 |
| Biagioni, S | 1 |
| Lupo, G | 1 |
| Rinaldi, A | 1 |
| De Jaco, A | 1 |
| Cacci, E | 1 |
| Arora, A | 1 |
| Becker, M | 1 |
| Marques, C | 1 |
| Oksanen, M | 1 |
| Li, D | 1 |
| Mastropasqua, F | 1 |
| Watts, ME | 1 |
| Arora, M | 1 |
| Falk, A | 1 |
| Daub, CO | 1 |
| Lanekoff, I | 1 |
| Tammimies, K | 1 |
| King, BH | 1 |
| Ne'eman, A | 1 |
| Albrecht, K | 1 |
| Kapp, SK | 1 |
| Kaushik, G | 2 |
| Xia, Y | 2 |
| Pfau, JC | 1 |
| Thomas, MA | 3 |
| Lu, ZA | 1 |
| Mu, W | 1 |
| Osborne, LM | 1 |
| Cordner, ZA | 1 |
| Herscu, P | 1 |
| Handen, BL | 1 |
| Arnold, LE | 1 |
| Snape, MF | 1 |
| Bregman, JD | 1 |
| Ginsberg, L | 1 |
| Hendren, R | 1 |
| Kolevzon, A | 1 |
| Melmed, R | 1 |
| Mintz, M | 1 |
| Minshew, N | 1 |
| Sikich, L | 1 |
| Attalla, A | 1 |
| King, B | 1 |
| Owley, T | 1 |
| Childress, A | 1 |
| Chugani, H | 1 |
| Frazier, J | 1 |
| Cartwright, C | 2 |
| Murphy, T | 1 |
| Williams, K | 2 |
| Brignell, A | 1 |
| Randall, M | 1 |
| Silove, N | 2 |
| Hazell, P | 3 |
| Chantiluke, K | 1 |
| Barrett, N | 1 |
| Giampietro, V | 1 |
| Brammer, M | 1 |
| Simmons, A | 1 |
| Murphy, DG | 1 |
| Rubia, K | 1 |
| Mouti, A | 1 |
| Reddihough, D | 1 |
| Marraffa, C | 1 |
| Wray, J | 1 |
| Lee, K | 1 |
| Kohn, M | 1 |
| Luongo, FJ | 1 |
| Horn, ME | 1 |
| Sohal, VS | 1 |
| Yang, L | 1 |
| Ghaziuddin, N | 2 |
| Gih, D | 1 |
| Barbosa, V | 1 |
| Maixner, DF | 1 |
| Ghaziuddin, M | 3 |
| Wheeler, DM | 1 |
| Chadman, KK | 1 |
| Makkonen, I | 1 |
| Kokki, H | 1 |
| Kuikka, J | 1 |
| Turpeinen, U | 1 |
| Riikonen, R | 1 |
| Klaper, RD | 1 |
| DeLong, GR | 2 |
| Ritch, CR | 1 |
| Burch, S | 1 |
| Albertini, G | 3 |
| Majolini, L | 3 |
| Di Gennaro, G | 3 |
| Quarato, P | 3 |
| Scoppetta, C | 3 |
| Onorati, P | 3 |
| Moore, ML | 1 |
| Eichner, SF | 1 |
| Jones, JR | 1 |
| Hollander, E | 3 |
| Phillips, A | 1 |
| Chaplin, W | 2 |
| Zagursky, K | 1 |
| Novotny, S | 1 |
| Wasserman, S | 2 |
| Iyengar, R | 1 |
| Anagnostou, E | 1 |
| Esposito, K | 1 |
| Soorya, L | 1 |
| Koshes, RJ | 1 |
| Damore, J | 1 |
| Stine, J | 1 |
| Brody, L | 1 |
| Fatemi, SH | 1 |
| Realmuto, GM | 1 |
| Khan, L | 1 |
| Thuras, P | 1 |
| Teague, LA | 1 |
| McSwain Kamran, M | 1 |
| Branford, D | 1 |
| Bhaumik, S | 1 |
| Naik, B | 1 |
| Storch, DD | 1 |
| Blatt, SD | 1 |
| Meguid, V | 1 |
| Church, CC | 1 |
| Botash, AS | 1 |
| Jean-Louis, F | 1 |
| Siripornsawan, MP | 1 |
| Weinberger, HL | 1 |
| Granana, N | 1 |
| Tuchman, RF | 1 |
| Peral, M | 1 |
| AlcamÃ, M | 1 |
| Gilaberte, I | 1 |
| Buchsbaum, MS | 1 |
| Haznedar, MM | 1 |
| Tang, C | 1 |
| Spiegel-Cohen, J | 1 |
| Wei, TC | 1 |
| Solimando, A | 1 |
| Buchsbaum, BR | 1 |
| Robins, D | 1 |
| Bienstock, C | 1 |
| Mosovich, S | 1 |
| Strauss, WL | 1 |
| Unis, AS | 1 |
| Cowan, C | 1 |
| Dawson, G | 1 |
| Dager, SR | 1 |
| Rickards, EH | 1 |
| Prendergast, M | 1 |
| Cook, EH | 1 |
| Rowlett, R | 1 |
| Jaselskis, C | 1 |
| Leventhal, BL | 1 |
| Tsai, L | 2 |
| Todd, RD | 1 |
| Hamdan-Allen, G | 1 |
| Friedman, EH | 1 |
| Mehlinger, R | 1 |
| Scheftner, WA | 1 |
| Poznanski, E | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Study Of Fluoxetine In Autism: A Randomised, Double-Blind, Placebo-Controlled, Parallel-Group 14-Week Study To Investigate The Effect Of Fluoxetine Orally Dissolving Tablet (ODT) On Repetitive Behaviors In Childhood And Adolescent Autistic Disorder.[NCT00515320] | Phase 3 | 158 participants (Actual) | Interventional | 2007-08-31 | Completed | ||
| A Double Blind, Randomized, Placebo-Controlled Study of CM-AT for the Treatment of Autism in Children With All Levels of Fecal Chymotrypsin (FCT)[NCT02410902] | Phase 3 | 190 participants (Actual) | Interventional | 2015-05-13 | Completed | ||
| An Open-Label Extension Study of CM-AT for the Treatment of Children With Autism With All Levels of Fecal Chymotrypsin[NCT02649959] | Phase 3 | 405 participants (Anticipated) | Interventional | 2015-10-31 | Active, not recruiting | ||
| [NCT00004486] | 45 participants | Interventional | 1998-09-30 | Completed | |||
| Galantamine Versus Placebo in Childhood Autism[NCT00252603] | Phase 3 | 20 participants | Interventional | 2004-04-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Primary outcome measurements to determine efficacy of treatment with CM-AT versus Placebo for changes in the Aberrant Behavior Checklist (ABC) - Community sub scale for Irritability/Agitation (ABC-I) between baseline (subject's initial measurement) and Week 12/Termination (subject's final measurement) visit. Participants were between 3 through to 6 years old inclusive and took 900mg CM-AT or Placebo three times daily. The ABC-I is one of five discrete sub scales measured by the ABC. The scale range is 0-45. A higher score reflects higher severity of symptoms (irritability). Scores are obtained via Parent Rated Questionnaire. Parents respond to a series of questions on a scale directly into an electronic data capture system (EDC), responding: 0 = not at all a problem 1 = the behavior is a problem but slight in degree 2 = the problem is moderately serious 3 = the problem is severe in degree. The score was automatically calculated by the EDC. (NCT02410902)
Timeframe: Screening through Week 12/Termination
| Intervention | units on a scale (Mean) |
|---|---|
| CM-AT | -8.0 |
| Placebo | -5.5 |
Secondary outcome measurements to determine efficacy of treatment with CM-AT versus Placebo for changes in the Aberrant Behavior Checklist- Community (ABC) sub scale for Lethargy / Social Withdrawal (ABC-L) between baseline (subject's initial measurement) and Week 12/Termination (subject's final measurement) visit. Participants were between 3 through to 6 years old inclusive and took 900mg CM-AT or Placebo three times daily. The ABC-L is one of five discrete sub scales measured by the ABC. The scale range is 0-48. A higher score reflects higher severity of symptoms (lethargy). Scores are obtained via Parent Rated Questionnaire. Parents respond to a series of questions on a scale directly into an electronic data capture system (EDC), responding: 0 = not at all a problem 1 = the behavior is a problem but slight in degree 2 = the problem is moderately serious 3 = the problem is severe in degree. (NCT02410902)
Timeframe: Screening through Week 12/Termination.
| Intervention | units on a scale (Mean) |
|---|---|
| CM-AT | -7.9 |
| Placebo | -6.6 |
4 reviews available for fluoxetine and Autism
| Article | Year |
|---|---|
Selective serotonin reuptake inhibitors (SSRIs) for autism spectrum disorders (ASD).
Topics: Adult; Age Factors; Autistic Disorder; Child; Child Development Disorders, Pervasive; Citalopram; Fe | 2013 |
Selective serotonin reuptake inhibitors (SSRIs) for autism spectrum disorders (ASD).
Topics: Adult; Age Factors; Autistic Disorder; Child; Citalopram; Fenfluramine; Fluoxetine; Fluvoxamine; Hum | 2010 |
Selective serotonin reuptake inhibitors (SSRIs) for autism spectrum disorders (ASD).
Topics: Adult; Age Factors; Autistic Disorder; Child; Citalopram; Fenfluramine; Fluoxetine; Fluvoxamine; Hum | 2010 |
Selective serotonin reuptake inhibitors (SSRIs) for autism spectrum disorders (ASD).
Topics: Adult; Age Factors; Autistic Disorder; Child; Citalopram; Fenfluramine; Fluoxetine; Fluvoxamine; Hum | 2010 |
Selective serotonin reuptake inhibitors (SSRIs) for autism spectrum disorders (ASD).
Topics: Adult; Age Factors; Autistic Disorder; Child; Citalopram; Fenfluramine; Fluoxetine; Fluvoxamine; Hum | 2010 |
Treating functional impairment of autism with selective serotonin-reuptake inhibitors.
Topics: Autistic Disorder; Citalopram; Clinical Trials as Topic; Fluoxetine; Fluvoxamine; Humans; Paroxetine | 2004 |
Sudden infant death syndrome, child sexual abuse, and child development.
Topics: Autistic Disorder; Child; Child Abuse, Sexual; Child, Preschool; Condylomata Acuminata; Fluoxetine; | 1999 |
9 trials available for fluoxetine and Autism
| Article | Year |
|---|---|
The SOFIA Study: Negative Multi-center Study of Low Dose Fluoxetine on Repetitive Behaviors in Children and Adolescents with Autistic Disorder.
Topics: Adolescent; Autistic Disorder; Child; Child, Preschool; Dose-Response Relationship, Drug; Double-Bli | 2020 |
Inverse Effect of Fluoxetine on Medial Prefrontal Cortex Activation During Reward Reversal in ADHD and Autism.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Autistic Disorder; Brain Mapping; Child; | 2015 |
Fluoxetine for Autistic Behaviors (FAB trial): study protocol for a randomized controlled trial in children and adolescents with autism.
Topics: Adolescent; Adolescent Behavior; Autistic Disorder; Child; Child Behavior; Double-Blind Method; Drug | 2014 |
Effects of fluoxetine treatment on striatal dopamine transporter binding and cerebrospinal fluid insulin-like growth factor-1 in children with autism.
Topics: Adolescent; Autistic Disorder; Child; Child, Preschool; Corpus Striatum; Dopamine Plasma Membrane Tr | 2011 |
A placebo controlled crossover trial of liquid fluoxetine on repetitive behaviors in childhood and adolescent autism.
Topics: Administration, Oral; Adolescent; Autistic Disorder; Child; Cross-Over Studies; Cumulative Trauma Di | 2005 |
Divalproex versus placebo for the prevention of irritability associated with fluoxetine treatment in autism spectrum disorder.
Topics: Antidepressive Agents, Second-Generation; Antimanic Agents; Autistic Disorder; Child; Double-Blind M | 2006 |
Fluoxetine in treatment of adolescent patients with autism: a longitudinal open trial.
Topics: Adolescent; Adult; Autistic Disorder; Behavioral Symptoms; Child; Female; Fluoxetine; Humans; Longit | 1998 |
Fluoxetine in children with autism.
Topics: Autistic Disorder; Child; Child Behavior Disorders; Child, Preschool; Female; Fluoxetine; Humans; Ma | 1999 |
Effect of fluoxetine on regional cerebral metabolism in autistic spectrum disorders: a pilot study.
Topics: Adult; Analysis of Variance; Antidepressive Agents, Second-Generation; Asperger Syndrome; Autistic D | 2001 |
28 other studies available for fluoxetine and Autism
| Article | Year |
|---|---|
Adult hippocampal neurogenesis and social behavioural deficits in the R451C Neuroligin3 mouse model of autism are reverted by the antidepressant fluoxetine.
Topics: Animals; Antidepressive Agents; Autism Spectrum Disorder; Autistic Disorder; Disease Models, Animal; | 2023 |
Screening autism-associated environmental factors in differentiating human neural progenitors with fractional factorial design-based transcriptomics.
Topics: Autism Spectrum Disorder; Autistic Disorder; Fluoxetine; Humans; Induced Pluripotent Stem Cells; Res | 2023 |
Fluoxetine and Repetitive Behaviors in Children and Adolescents With Autism Spectrum Disorder.
Topics: Adolescent; Autism Spectrum Disorder; Autistic Disorder; Child; Cognition; Compulsive Behavior; Fluo | 2019 |
Obsessive-Compulsive Behaviors in Autism.
Topics: Adolescent; Autism Spectrum Disorder; Autistic Disorder; Child; Compulsive Behavior; Fluoxetine; Hum | 2020 |
Dysregulation of autism-associated synaptic proteins by psychoactive pharmaceuticals at environmental concentrations.
Topics: Animals; Autism Spectrum Disorder; Autistic Disorder; Brain; Carbamazepine; Environment; Female; Flu | 2017 |
Eighteen-year-old man with autism, obsessive compulsive disorder and a
Topics: Adolescent; Anorexia; Autistic Disorder; Fluoxetine; Humans; Male; Nerve Tissue Proteins; Obsessive- | 2018 |
Putative Microcircuit-Level Substrates for Attention Are Disrupted in Mouse Models of Autism.
Topics: Action Potentials; Animals; Attention; Autistic Disorder; Calcium; Disease Models, Animal; Fluoxetin | 2016 |
Psychoactive pharmaceuticals at environmental concentrations induce in vitro gene expression associated with neurological disorders.
Topics: Animals; Autistic Disorder; Carbamazepine; Cell Line, Tumor; Environmental Pollutants; Fluoxetine; G | 2016 |
Onset of catatonia at puberty: electroconvulsive therapy response in two autistic adolescents.
Topics: Adolescent; Age of Onset; Aggression; Antidepressive Agents, Second-Generation; Antipsychotic Agents | 2010 |
Fluoxetine but not risperidone increases sociability in the BTBR mouse model of autism.
Topics: Animals; Autistic Disorder; Behavior, Animal; Disease Models, Animal; Fluoxetine; Male; Mice; Risper | 2011 |
Psychoactive pharmaceuticals induce fish gene expression profiles associated with human idiopathic autism.
Topics: Animals; Autistic Disorder; Carbamazepine; Cell Adhesion Molecules; Cyclohexanols; Cyprinidae; Fluox | 2012 |
Fluoxetine response in children with autistic spectrum disorders: correlation with familial major affective disorder and intellectual achievement.
Topics: Autistic Disorder; Bipolar Disorder; Child; Child, Preschool; Cluster Analysis; Depressive Disorder, | 2002 |
Oral dyskinesia induced by fluoxetine therapy for infantile autism.
Topics: Autistic Disorder; Dyskinesia, Drug-Induced; Fluoxetine; Humans; Infant; Male; Selective Serotonin R | 2004 |
Use of fluoxetine for obsessive-compulsive behavior in adults with autism.
Topics: Adult; Autistic Disorder; Female; Fluoxetine; Humans; Male; Obsessive-Compulsive Disorder | 1997 |
Medication-induced hypomania in Asperger's disorder.
Topics: Antimanic Agents; Attention Deficit Disorder with Hyperactivity; Autistic Disorder; Bipolar Disorder | 1998 |
Effects of fluoxetine treatment in young children with idiopathic autism.
Topics: Antidepressive Agents; Autistic Disorder; Child; Child, Preschool; Female; Fluoxetine; Humans; Langu | 1998 |
Selective serotonin re-uptake inhibitors for the treatment of perseverative and maladaptive behaviours of people with intellectual disability.
Topics: Adult; Autistic Disorder; Drug Therapy, Combination; England; Female; Fluoxetine; Humans; Intellectu | 1998 |
Medication-induced hypomania in Asperger's disorder.
Topics: Affective Symptoms; Attention Deficit and Disruptive Behavior Disorders; Autistic Disorder; Child; C | 1999 |
A child with severe head banging.
Topics: Autistic Disorder; Child; Fluoxetine; Humans; Male; Obsessive-Compulsive Disorder; Selective Seroton | 1999 |
Fluorine magnetic resonance spectroscopy measurement of brain fluvoxamine and fluoxetine in pediatric patients treated for pervasive developmental disorders.
Topics: Adolescent; Adult; Age Factors; Autistic Disorder; Brain; Brain Chemistry; Child; Child Development | 2002 |
Fluoxetine and serotonin in autism.
Topics: Autistic Disorder; Fluoxetine; Humans; Serotonin | 1992 |
Fluoxetine treatment of children and adults with autistic disorder and mental retardation.
Topics: Adolescent; Adult; Autistic Disorder; Child; Female; Fluoxetine; Humans; Intellectual Disability; Ma | 1992 |
Depression in autistic disorder.
Topics: Adolescent; Arousal; Autistic Disorder; Depressive Disorder; Down Syndrome; Fluoxetine; Humans; Male | 1991 |
Fluoxetine in autism.
Topics: Adolescent; Adult; Autistic Disorder; Child; Drug Administration Schedule; Female; Fluoxetine; Human | 1991 |
Brief report: trichotillomania in an autistic male.
Topics: Adolescent; Arousal; Autistic Disorder; Fluoxetine; Follow-Up Studies; Humans; Male; Stereotyped Beh | 1991 |
Adverse effects of fluoxetine.
Topics: Adult; Autistic Disorder; Drug Administration Schedule; Female; Fluoxetine; Humans | 1991 |
Fluoxetine in autism with depression.
Topics: Adolescent; Adult; Autistic Disorder; Depressive Disorder; Female; Fluoxetine; Humans; Male | 1991 |
Fluoxetine and autism.
Topics: Adult; Autistic Disorder; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fl | 1990 |